Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
05/23/2017 05/24/2017 05/26/2017 05/29/2017 05/30/2017 Date
79.05(c) 79.1(c) 78.6(c) 78.5(c) 78.5 Last
4 945 564 4 069 776 4 008 322 1 862 666 1 879 899 Volume
-0.44% +0.06% -0.63% -0.13% 0.00% Change
More quotes
Financials ($)
Sales 2017 48 305 M
EBIT 2017 11 823 M
Net income 2017 7 499 M
Debt 2017 13 918 M
Yield 2017 3,53%
Sales 2018 50 129 M
EBIT 2018 12 839 M
Net income 2018 8 520 M
Debt 2018 11 962 M
Yield 2018 3,71%
P/E ratio 2017 24,14
P/E ratio 2018 21,27
EV / Sales2017 4,65x
EV / Sales2018 4,44x
Capitalization 210 841 M
More Financials
Company
Novartis AG develops, manufactures, and markets healthcare products.It operates through the following segments: Pharmaceuticals, Alcon, Sandoz, and Corporate Activities.The Pharmaceuticals segment provides patent-protected prescription medicines.The Alcon segment offers surgical, ophthalmic... 
Sector
Pharmaceuticals
Calendar
05/30Shareholder meeting
More about the company
Surperformance© ratings of Novartis AG
Trading Rating : Investor Rating :
More Ratings
Latest news on NOVARTIS AG
02:00p THE UPS AND DOWNS OF NOVARTIS AG (AD : NVS)’s Latest Approval
05/26 NOVARTIS : receives FDA approval for expanded use of Zykadia® in first-line ALK-..
05/26 NOVARTIS : CONTRACT AWARD - Rivastigmine 24 hr Patch
05/26 NOVARTIS : MILITARY $13.85 Million Federal Contract Awarded to Sandoz
05/25 NOVARTIS : data at ASCO, ICML and EHA meetings demonstrate meaningful advancemen..
05/24 WEAK Q4 : Novartis India plunges over 4%
05/24 NOVARTIS INDIA : posts Q4 net at Rs 2.91 crore
05/23 NOVARTIS : ' new analyses reinforce the potential of Ultibro® Breezhaler® for CO..
05/19 NOVARTIS : receives positive CHMP opinion for first-line use of Zykadia® in ALK-..
05/18 NOVARTIS : receives FDA approval for first-of-its-kind Kisqali® Femara® Co-Pack ..
More news
Sector news : Pharmaceuticals - NEC
05/29 WARREN BUFFETT : Warren Buffett takes 3 percent stake in Germany's Lanxess
05/29DJMERCK : Congo Approves Anti-Ebola Vaccine to Combat Outbreak in Remote Northeast
05/26DJSUN PHARMACEUTICAL INDUSTRIES : Pharma 4Q Profit Falls 13.6%
05/24 JOHNSON & JOHNSON : J&J settles drug manufacturing probe by U.S. states for $33 ..
05/24 FTSE edges up helped by M&S, but miners weigh
More sector news : Pharmaceuticals - NEC
4-Traders Strategies on NOVARTIS AG 
2016A trend reversal can be anticipated
More Strategies
Latest Tweets
03:01pComerica Bank Raises Position in Novartis AG $NVS  
03:01pNovartis is considering asset sales that could raise $50 billion, but some in.. 
02:38p$NVS (-0.4% pre) Novartis has assets to sell, investors wary of what it might..
1
02:02pIntellia Therapeutics Inc $NTLA Receives Average Recommendation of “Buy” from.. 
01:21pKite gets FDA priority review for KTE-C19, putting it 2 months behind Novarti.. 
More tweets
Qtime:252
News from SeekingAlpha
05/28 3 THINGS IN BIOTECH YOU SHOULD LEARN : May 28, 2017
05/26 FDA OKs expanded use of Novartis cancer med Zykadia
05/26 Therapy Focus - Not Quite The Hammer For Sickle Cell Disease
05/26 Renal Cancer Data For Acceleron's And Coherus' Biosimilars' Date With The FDA
05/25 FDA drug approvals rebound from last year, up over 100% yoy
Advertisement
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 32
Average target price 80,3 $
Spread / Average Target -0,01%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Joseph Jimenez Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Kirsch Chief Financial Officer
Vasant Narasimhan Chief Medical Officer & Head-Drug Development
Srikant Madhav Datar Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS AG6.07%210 841
JOHNSON & JOHNSON10.16%341 901
ROCHE HOLDING LTD.14.62%235 172
PFIZER INC.-1.05%191 398
MERCK & CO., INC.10.28%177 567
SANOFI13.94%122 703
More Results